Winger, Jonathan A.Hantschel, OliverSuperti-Furga, GiulioKuriyan, John2011-03-212011-03-212011-03-21200910.1186/1472-6807-9-7https://infoscience.epfl.ch/handle/20.500.14299/65505Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.text::journal::journal article::research article